Monopex (Dexamethasone Phosphate)

Monopex (dexamethasone phosphate) is used to treat ocular inflammatory conditions by suppressing inflammatory pathways.

• Post‑operative ocular inflammation: reduces swelling, pain and redness after eye surgery.
• Uveitis: controls intra‑ocular inflammation and prevents tissue damage.
• Allergic conjunctivitis: alleviates itching, tearing and conjunctival edema.
• Other inflammatory eye conditions: provides broad anti‑inflammatory effect to improve visual comfort.

• Dexamethasone phosphate enters ocular cells and binds cytoplasmic glucocorticoid receptors. The drug‑receptor complex translocates to the nucleus, where it interacts with glucocorticoid response elements, altering gene transcription. This down‑regulates pro‑inflammatory cytokines, chemokines and adhesion molecules, while up‑regulating anti‑inflammatory proteins, leading to reduced vascular permeability and edema in ocular tissues. The rapid conversion of the phosphate ester to active dexamethasone within the eye ensures high local potency with minimal systemic exposure.

Dexamethasone phosphate may cause ocular and systemic adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Transient eye irritation: mild burning or stinging sensation that usually resolves within minutes.
• Increased intra‑ocular pressure: a modest rise that can be detected during routine tonometry.
• Blurred vision: temporary reduction in visual acuity that improves after the medication is cleared.
• Conjunctival hyperemia: mild redness of the eye surface without pain.

Serious or Rare Side Effects

• Secondary ocular infection: bacterial or fungal infection may develop due to local immunosuppression.
• Cataract formation: accelerated lens opacity can occur with long‑term therapy.
• Systemic glucocorticoid effects: adrenal suppression, hyperglycemia, or mood changes may appear if significant systemic absorption occurs.

When prescribing or handling Monopex, several precautions should be observed to minimize risks.

• Patient assessment: evaluate baseline intra‑ocular pressure and ocular infection status before initiating therapy.
• Duration of therapy: limit use to the shortest effective period to reduce risk of pressure rise and cataract.
• Monitoring: schedule regular eye examinations to detect pressure changes or lens opacities.
• Contraindications: avoid in patients with known hypersensitivity to dexamethasone or any formulation component.
• Systemic conditions: use caution in diabetic or hypertensive patients due to possible systemic absorption.
• Store at ambient temperature: keep below 25 °C, protect from light and moisture in the original container.

Dexamethasone phosphate can interact with other ophthalmic or systemic agents; awareness of these interactions helps ensure safe use.

Major Interactions (Avoid)

• Systemic CYP3A4 inducers: may reduce glucocorticoid efficacy if significant systemic absorption occurs.
• Anticholinergic eye drops: can increase risk of ocular hypertension when combined.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): concurrent use may increase risk of corneal melting.
• Antiviral agents (e.g., acyclovir): may require monitoring for delayed healing.
• Antifungal eye preparations: potential additive immunosuppression.
• Systemic steroids: additive systemic glucocorticoid effects should be evaluated.